Developer docs
API playgroundTry for free, no card

Search company profiles

Integral Molecular

Full company profile

uuid00025sj

Namestring
Integral Molecular
Legal namestring
Integral Molecular
Company typeenum
Private
Founded yearint
2001
Descriptiontext

Integral Molecular is a privately held biotechnology company founded in 2001 by University of Pennsylvania scientists and headquartered in Philadelphia, Pennsylvania. The company specializes in membrane protein research and therapeutic antibody discovery, operating a portfolio of proprietary technology platforms including the Membrane Proteome Array (MPA) for specificity testing against 6,000+ human membrane proteins, Lipoparticle virus-like particle technology for presenting conformationally intact membrane proteins, the MPS Antibody Discovery Platform using divergent (chicken) immunization against challenging targets such as GPCRs and ion channels, Shotgun Mutagenesis Epitope Mapping at single amino acid resolution, Paratope-PLUS CDR-Scanning for genus-level patent enablement, and Reporter Virus Particles for safe viral neutralization assays.

The company generates revenue through four streams: fee-for-service contract research (specificity testing, antibody discovery, epitope mapping), reagent and product sales (Lipoparticles, virology reagents), therapeutic asset licensing (programs including CLDN6 licensed to Context Therapeutics, CLDN18.2 licensed to Cartexell, and undisclosed oncology targets licensed to AstraZeneca), and success-based pricing for Target Identification projects. It serves more than 600 customers and partners including all Top 20 pharmaceutical companies, with named clients spanning AstraZeneca, Pfizer, Merck, Novartis, Boehringer Ingelheim, Ono Pharmaceutical, Merus, Sutro Biopharma, and Cabaletta Bio. MPA specificity data has been accepted in over 100 IND filings by the FDA, EMA, and NMPA.

The company distributes services through direct enterprise sales with scientific consultation and maintains a global distributor network for virology reagents (Scientist.com, KRISHGEN Bio Systems, Sung Woo, Funakoshi) plus a dedicated e-commerce platform. Operations are based at a 50,000 sq. ft. facility at One uCity Square in Philadelphia, with the regional workforce expanded to 200+ following a 2023 $1M Commonwealth of Pennsylvania grant. The company has been profitable since inception and has operated primarily on approximately $21 million in non-dilutive NIH and state grants over its 25-year history, remaining founder-owned and led by President and CEO Benjamin Doranz (PhD, MBA).

Short descriptiontext

Integral Molecular is a privately held Philadelphia biotechnology company developing proprietary membrane protein technologies and therapeutic antibody discovery platforms. It serves 600+ pharmaceutical and biotechnology customers including all Top 20 pharma with fee-for-service research, reagents, and therapeutic licensing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersPhiladelphia, United States
HQ citystring
Philadelphia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
membrane protein technologies, antibody specificity testing, therapeutic antibody discovery, virology reagent products, epitope mapping services
Industry7 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Antibody Discovery and Characterization Services
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Fee-for-Service Contract Research
TypeProfessional Services
Description

Project-based fee-for-service arrangements for antibody discovery, specificity testing, epitope mapping, and other技术服务. Customers pay for specific research services with defined deliverables.

integralmolecular.com
2Reagent and Product Sales
TypeHardware Sales
Description

Sale of virology reagents including Reporter Virus Particles, ReadyReceptor Lipoparticles, and custom reagent products. Products available through direct ordering and distributor network.

integralmolecular.com
3Therapeutic Asset Licensing
TypeLicensing Royalties
Description

Licensing of proprietary therapeutic antibody assets discovered using MPS platform. Includes CLDN6, CLDN18.2, GPRC5D, CCR8, P2X3, and P2X7 programs. Licensing models range from straight-out licensing to joint research collaborations.

integralmolecular.com
4Success-Based Pricing
TypeProfessional Services
Description

Target Identification services offered with success-based pricing structure where customers pay lower fees if screening does not identify validated targets, protecting customer investment.

integralmolecular.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
Pricing details3 tiers
1Standard MPA Specificity Testing - 8-week turnaround
ModelOtherBilling cadencePay-as-you-go
Notes

Standard Membrane Proteome Array projects including screening against 6,000+ membrane proteins with hit validation. Requires approximately 500 µg of each antibody.

integralmolecular.com
2MPA+IND Regulatory Submission Service - 4-week turnaround
ModelOtherBilling cadencePay-as-you-go
Notes

Accelerated service with IND-ready study report, additional controls, QA documentation, audit support, and 10-year records retention for regulatory filings.

integralmolecular.com
3Target Identification Projects - 8-10 week turnaround
ModelOutcome Based/ PerformanceBilling cadencePay-as-you-go
Notes

Success-based pricing structure where fee is lower if screen does not identify validated target. Approximately 80% success rate in identifying at least 1 validated target.

integralmolecular.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Membrane Proteome Array (MPA)
Description

Cell-based protein array for antibody specificity testing against 6,000+ human membrane proteins

integralmolecular.com
+5 more records
Core offering1 text field

Integral Molecular provides cell-based antibody specificity testing services using its Membrane Proteome Array (MPA) platform that screens biotherapeutics against 6,000+ human membrane proteins in unfixed cells. The company also offers therapeutic antibody discovery using the MPS platform with Lipoparticle and chicken immunization technology, high-resolution Shotgun Mutagenesis epitope mapping, Paratope-PLUS CDR-Scanning for antibody IP protection, and a portfolio of virology reagents including Reporter Virus Particles and Ready Reporter Virus kits for neutralization assays.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 1 in 3 antibody drug candidates demonstrate off-target binding, making specificity testing essential for patient safety
+5 more records
Product overview1 text field

Integral Molecular is a biotechnology company offering a portfolio of technology platforms and services for membrane protein research and antibody therapeutics discovery. The core products include the Membrane Proteome Array™ (MPA) for antibody specificity testing against 6,000+ membrane proteins, the MPS Antibody Discovery Platform for generating therapeutic antibodies against challenging targets like GPCRs and ion channels, and Lipoparticles™ (virus-like particles) for presenting membrane proteins in native conformation. Supporting platforms include Shotgun Mutagenesis Epitope Mapping for high-resolution antibody epitope characterization, Paratope-PLUS® CDR-Scanning for antibody IP protection and engineering, and a suite of virology reagents including Reporter Virus Particles and Ready Reporter Virus kits for neutralization assays. The company also offers specialized services including Target Identification using the MPA platform, MPA+IND for regulatory submissions, and Enhanced Binding Analysis for follow-up studies.

Product and service11 records
1Membrane Proteome Array (MPA)
CategorySpecificity Testing Service
Description

Cell-based protein array service that screens antibodies, CAR-T cells, ADCs, and other biotherapeutics against approximately 6,000 human membrane proteins (94% of the human membrane proteome) using unfixed cells and quantitative flow cytometry to identify off-target binding for pharmaceutical and biotech customers.

2Shotgun Mutagenesis Epitope Mapping
CategoryEpitope Mapping Service
Description

High-throughput service mapping conformational epitopes at single amino acid resolution using alanine-scanning mutation libraries expressed in live human cells, without requiring purified proteins. Over 1,500 epitopes mapped with >95% success rate.

3Paratope-PLUS CDR-Scanning
CategoryAntibody Characterization Service
Description

Site saturation mutagenesis service testing every possible amino acid substitution at each CDR residue to support antibody engineering and patent protection by identifying all permissible substitutions that retain or improve binding.

4Lipoparticles (Virus-Like Particles)
CategoryResearch Reagents
Description

Non-infectious virus-like particles containing high concentrations of conformationally intact membrane proteins at 10-100x cell concentration, used for antibody immunization and screening against GPCRs, ion channels, transporters, and immuno-oncology targets.

5MPS Antibody Discovery Platform
CategoryAntibody Discovery Service
Description

Therapeutic antibody discovery service specifically designed for challenging membrane protein targets including GPCRs, ion channels, and transporters. Uses Lipoparticle, RNA, and DNA antigens with chickens as divergent immunization hosts to deliver diverse panels of humanized monoclonal antibodies with >95% success rate.

6Reporter Virus Particles (RVPs)
CategoryVirology Reagents
Description

Non-replicative pseudotyped viral particles used as BSL-2 safe alternatives to live virus for infectivity and neutralization assays across influenza, SARS-CoV-2, dengue, Zika, Chikungunya, Ebola, Marburg, and Nipah viruses. Trusted by 100+ laboratories.

7Ready Reporter Virus Kit
CategoryVirology Assay Kit
Description

Thaw-and-use neutralization assay kit that delivers results in under 4 hours using non-replicative virus particles displaying native viral proteins for safe and rapid virus neutralization testing.

8Influenza TiterSafe Particles
CategoryVirology Reagents
Description

Ready-to-use influenza reagent designed for easier hemagglutination inhibition (HAI) assays used by vaccine developers and serology laboratories.

9Neutralization Assay Services
CategoryVirology Testing Service
Description

Fee-for-service neutralization testing for antibody developers requiring neutralization data on their candidates.

10Target Identification Services
CategoryTarget Identification Service
Description

Uses the Membrane Proteome Array to identify unknown targets of antibodies, serum samples, or recombinant proteins. Also known as target deconvolution, antibody deorphaning, or target discovery. Success-based pricing available.

11ReadyMap Libraries
CategoryEpitope Mapping Reagents
Description

Pre-constructed, pre-validated epitope mapping libraries updated regularly with new targets to enable faster turnaround and lower cost shotgun mutagenesis epitope mapping projects.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnership and license agreement for novel therapeutic monoclonal antibodies. Merus stated that Integral Molecular's capabilities complement their ability to advance their therapeutic pipeline dedicated to delivering novel antibody therapeutics to patients.

2Ono Pharmaceutical
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Antibody discovery collaboration. Ono Pharmaceutical stated they were impressed by Integral Molecular's membrane protein expertise and proven record in discovering antibodies against membrane proteins.

integralmolecular.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Online marketplace distributor for virology reagents. Enables researchers to discover and purchase Integral Molecular products through Scientist.com's procurement platform.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Korean market offering Integral Molecular virology reagents and products.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Korean market offering Integral Molecular virology reagents and products.

6Funakoshi
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Regional distributor for Japanese market offering Integral Molecular virology reagents and products.

integralmolecular.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Retrogenix (Charles River Laboratories)
TypeDirect peer
Description

Retrogenix offers a cell-based protein microarray for antibody and protein specificity screening against human membrane proteins, the most direct competitor to Integral Molecular's Membrane Proteome Array. It was acquired by Charles River Laboratories, giving it significant commercial reach.

TypeDirect peer
Description

AbCellera operates a single-cell antibody discovery platform partnering with pharma to develop therapeutic antibodies. Comparable in serving large pharma with antibody discovery services and licensing programs, though its discovery engine is single-cell sequencing rather than membrane-protein focused.

TypeDirect peer
Description

Adimab is a private antibody discovery and engineering platform serving pharma and biotech partners. Directly comparable in providing fee-for-service and partnered therapeutic antibody discovery with a mature CRO-style business model.

TypeBroad incumbent
Description

Charles River is a large CRO offering discovery, safety assessment, and biologics services. Comparable as a partner of choice for pharma antibody programs, with the Retrogenix acquisition putting it in direct competition with Integral Molecular's specificity testing offering.

TypeBroad incumbent
Description

WuXi Biologics is a global biologics CRO/CDMO providing antibody discovery, cell line development, and manufacturing services. Comparable as an enterprise-scale service provider for pharma antibody pipelines, with broader scope than Integral Molecular.

TypeBroad incumbent
Description

Eurofins is a global bioanalytical testing services group with extensive capabilities in pharmacology, ADME, and immunology. Comparable as a large-scale CRO partner for biopharma safety and specificity testing requirements.

TypeBroad incumbent
Description

GenScript offers antibody discovery, protein production, and biologics CDMO services. Comparable in providing fee-for-service antibody discovery and protein engineering services to pharma and academic customers.

TypeDirect peer
Description

Antibody Solutions is a focused antibody discovery CRO offering custom monoclonal antibody generation services. Comparable as a smaller-scale specialty CRO targeting therapeutic antibody discovery for biotech and pharma clients.

TypeEmerging player
Description

Alloy Therapeutics operates a distributed antibody discovery platform with ATX-Gx transgenic mice, complementing Integral Molecular's chicken-based discovery. The companies are also technology partners, indicating overlap in antibody discovery infrastructure for biotech.

TypeBroad incumbent
Description

Crown Bioscience is a CRO providing preclinical and translational services for oncology and immuno-oncology drug development. Comparable in offering fee-for-service research supporting therapeutic antibody development pipelines of pharmaceutical sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers17 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Integral Molecular

Antibody Discovery and Characterization Servicesintegralmolecular.com

Integral Molecular is a privately held Philadelphia biotechnology company developing proprietary membrane protein technologies and therapeutic antibody discovery platforms. It serves 600+ pharmaceutical and biotechnology customers including all Top 20 pharma with fee-for-service research, reagents, and therapeutic licensing.

What Integral Molecular does

Integral Molecular is a privately held biotechnology company founded in 2001 by University of Pennsylvania scientists and headquartered in Philadelphia, Pennsylvania. The company specializes in membrane protein research and therapeutic antibody discovery, operating a portfolio of proprietary technology platforms including the Membrane Proteome Array (MPA) for specificity testing against 6,000+ human membrane proteins, Lipoparticle virus-like particle technology for presenting conformationally intact membrane proteins, the MPS Antibody Discovery Platform using divergent (chicken) immunization against challenging targets such as GPCRs and ion channels, Shotgun Mutagenesis Epitope Mapping at single amino acid resolution, Paratope-PLUS CDR-Scanning for genus-level patent enablement, and Reporter Virus Particles for safe viral neutralization assays.

The company generates revenue through four streams: fee-for-service contract research (specificity testing, antibody discovery, epitope mapping), reagent and product sales (Lipoparticles, virology reagents), therapeutic asset licensing (programs including CLDN6 licensed to Context Therapeutics, CLDN18.2 licensed to Cartexell, and undisclosed oncology targets licensed to AstraZeneca), and success-based pricing for Target Identification projects. It serves more than 600 customers and partners including all Top 20 pharmaceutical companies, with named clients spanning AstraZeneca, Pfizer, Merck, Novartis, Boehringer Ingelheim, Ono Pharmaceutical, Merus, Sutro Biopharma, and Cabaletta Bio. MPA specificity data has been accepted in over 100 IND filings by the FDA, EMA, and NMPA.

The company distributes services through direct enterprise sales with scientific consultation and maintains a global distributor network for virology reagents (Scientist.com, KRISHGEN Bio Systems, Sung Woo, Funakoshi) plus a dedicated e-commerce platform. Operations are based at a 50,000 sq. ft. facility at One uCity Square in Philadelphia, with the regional workforce expanded to 200+ following a 2023 $1M Commonwealth of Pennsylvania grant. The company has been profitable since inception and has operated primarily on approximately $21 million in non-dilutive NIH and state grants over its 25-year history, remaining founder-owned and led by President and CEO Benjamin Doranz (PhD, MBA).

Integral Molecular firmographics

Firmographics
Name
Integral Molecular
Legal name
Integral Molecular
Website
https://integralmolecular.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
101–250 employees
Short description
Integral Molecular is a privately held Philadelphia biotechnology company developing proprietary membrane protein technologies and therapeutic antibody discovery platforms. It serves 600+ pharmaceutical and biotechnology customers including all Top 20 pharma with fee-for-service research, reagents, and therapeutic licensing.
Ownership category
akta.pro rank

Integral Molecular industry classification

Industry
Product category
Antibody Discovery and Characterization Services
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Membrane protein technologies
  • Antibody specificity testing
  • Therapeutic antibody discovery
  • Virology reagent products
  • Epitope mapping services

Where Integral Molecular is headquartered

Location

Headquarters

HQ city
Philadelphia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Integral Molecular business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Fee-for-Service Contract Research: Project-based fee-for-service arrangements for antibody discovery, specificity testing, epitope mapping, and other技术服务. Customers pay for specific research services with defined deliverables.
  2. Reagent and Product Sales: Sale of virology reagents including Reporter Virus Particles, ReadyReceptor Lipoparticles, and custom reagent products. Products available through direct ordering and distributor network.
  3. Therapeutic Asset Licensing: Licensing of proprietary therapeutic antibody assets discovered using MPS platform. Includes CLDN6, CLDN18.2, GPRC5D, CCR8, P2X3, and P2X7 programs. Licensing models range from straight-out licensing to joint research collaborations.
  4. Success-Based Pricing: Target Identification services offered with success-based pricing structure where customers pay lower fees if screening does not identify validated targets, protecting customer investment.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goStandard MPA Specificity Testing - 8-week turnaround
OtherPay-as-you-goMPA+IND Regulatory Submission Service - 4-week turnaround
Outcome Based/ PerformancePay-as-you-goTarget Identification Projects - 8-10 week turnaround

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

Integral Molecular product offering

Product offering

Core offering

Integral Molecular provides cell-based antibody specificity testing services using its Membrane Proteome Array (MPA) platform that screens biotherapeutics against 6,000+ human membrane proteins in unfixed cells. The company also offers therapeutic antibody discovery using the MPS platform with Lipoparticle and chicken immunization technology, high-resolution Shotgun Mutagenesis epitope mapping, Paratope-PLUS CDR-Scanning for antibody IP protection, and a portfolio of virology reagents including Reporter Virus Particles and Ready Reporter Virus kits for neutralization assays.

Product overview

Integral Molecular is a biotechnology company offering a portfolio of technology platforms and services for membrane protein research and antibody therapeutics discovery. The core products include the Membrane Proteome Array™ (MPA) for antibody specificity testing against 6,000+ membrane proteins, the MPS Antibody Discovery Platform for generating therapeutic antibodies against challenging targets like GPCRs and ion channels, and Lipoparticles™ (virus-like particles) for presenting membrane proteins in native conformation. Supporting platforms include Shotgun Mutagenesis Epitope Mapping for high-resolution antibody epitope characterization, Paratope-PLUS® CDR-Scanning for antibody IP protection and engineering, and a suite of virology reagents including Reporter Virus Particles and Ready Reporter Virus kits for neutralization assays. The company also offers specialized services including Target Identification using the MPA platform, MPA+IND for regulatory submissions, and Enhanced Binding Analysis for follow-up studies.

Differentiator

Problem solved

Functional benefit

Brands

  • Membrane Proteome Array (MPA): Cell-based protein array for antibody specificity testing against 6,000+ human membrane proteins
  • MPS Antibody Discovery Platform
  • Lipoparticle Technology
  • Shotgun Mutagenesis Epitope Mapping
  • Paratope-PLUS CDR-Scanning
  • Ready Reporter Virus (RRV) Kits

Products and services

  • Membrane Proteome Array (MPA) Cell-based protein array service that screens antibodies, CAR-T cells, ADCs, and other biotherapeutics against approximately 6,000 human membrane proteins (94% of the human membrane proteome) using unfixed cells and quantitative flow cytometry to identify off-target binding for pharmaceutical and biotech customers.
  • Shotgun Mutagenesis Epitope Mapping High-throughput service mapping conformational epitopes at single amino acid resolution using alanine-scanning mutation libraries expressed in live human cells, without requiring purified proteins. Over 1,500 epitopes mapped with >95% success rate.
  • Paratope-PLUS CDR-Scanning Site saturation mutagenesis service testing every possible amino acid substitution at each CDR residue to support antibody engineering and patent protection by identifying all permissible substitutions that retain or improve binding.
  • Lipoparticles (Virus-Like Particles) Non-infectious virus-like particles containing high concentrations of conformationally intact membrane proteins at 10-100x cell concentration, used for antibody immunization and screening against GPCRs, ion channels, transporters, and immuno-oncology targets.
  • MPS Antibody Discovery Platform Therapeutic antibody discovery service specifically designed for challenging membrane protein targets including GPCRs, ion channels, and transporters. Uses Lipoparticle, RNA, and DNA antigens with chickens as divergent immunization hosts to deliver diverse panels of humanized monoclonal antibodies with >95% success rate.
  • Reporter Virus Particles (RVPs) Non-replicative pseudotyped viral particles used as BSL-2 safe alternatives to live virus for infectivity and neutralization assays across influenza, SARS-CoV-2, dengue, Zika, Chikungunya, Ebola, Marburg, and Nipah viruses. Trusted by 100+ laboratories.
  • Ready Reporter Virus Kit Thaw-and-use neutralization assay kit that delivers results in under 4 hours using non-replicative virus particles displaying native viral proteins for safe and rapid virus neutralization testing.
  • Influenza TiterSafe Particles Ready-to-use influenza reagent designed for easier hemagglutination inhibition (HAI) assays used by vaccine developers and serology laboratories.
  • Neutralization Assay Services Fee-for-service neutralization testing for antibody developers requiring neutralization data on their candidates.
  • Target Identification Services Uses the Membrane Proteome Array to identify unknown targets of antibodies, serum samples, or recombinant proteins. Also known as target deconvolution, antibody deorphaning, or target discovery. Success-based pricing available.
  • ReadyMap Libraries Pre-constructed, pre-validated epitope mapping libraries updated regularly with new targets to enable faster turnaround and lower cost shotgun mutagenesis epitope mapping projects.

Quantifiable outcome

  • 1 in 3 antibody drug candidates demonstrate off-target binding, making specificity testing essential for patient safety
  • +5 more outcomes

Companies that use Integral Molecular

Customer profile

Named customers17 records

Segments5 records

Ideal customer profiles3 records

Integral Molecular technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Integral Molecular partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • MeruscoreStrategic or Co-development PartnerStrategic partnership and license agreement for novel therapeutic monoclonal antibodies. Merus stated that Integral Molecular's capabilities complement their ability to advance their therapeutic pipeline dedicated to delivering novel antibody therapeutics to patients.
  • Ono PharmaceuticalcoreStrategic or Co-development PartnerAntibody discovery collaboration. Ono Pharmaceutical stated they were impressed by Integral Molecular's membrane protein expertise and proven record in discovering antibodies against membrane proteins.
  • Scientist.comminorChannel Partner/ Reseller/ DistributorOnline marketplace distributor for virology reagents. Enables researchers to discover and purchase Integral Molecular products through Scientist.com's procurement platform.
  • KRISHGEN Bio SystemsminorChannel Partner/ Reseller/ DistributorRegional distributor for Korean market offering Integral Molecular virology reagents and products.
  • Sung WoominorChannel Partner/ Reseller/ DistributorRegional distributor for Korean market offering Integral Molecular virology reagents and products.
  • FunakoshiminorChannel Partner/ Reseller/ DistributorRegional distributor for Japanese market offering Integral Molecular virology reagents and products.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Integral Molecular competitors and assessment

Company assessment

Direct peers

  • Retrogenix (Charles River Laboratories): Retrogenix offers a cell-based protein microarray for antibody and protein specificity screening against human membrane proteins, the most direct competitor to Integral Molecular's Membrane Proteome Array. It was acquired by Charles River Laboratories, giving it significant commercial reach.
  • AbCellera Biologics: AbCellera operates a single-cell antibody discovery platform partnering with pharma to develop therapeutic antibodies. Comparable in serving large pharma with antibody discovery services and licensing programs, though its discovery engine is single-cell sequencing rather than membrane-protein focused.
  • Adimab: Adimab is a private antibody discovery and engineering platform serving pharma and biotech partners. Directly comparable in providing fee-for-service and partnered therapeutic antibody discovery with a mature CRO-style business model.
  • Antibody Solutions: Antibody Solutions is a focused antibody discovery CRO offering custom monoclonal antibody generation services. Comparable as a smaller-scale specialty CRO targeting therapeutic antibody discovery for biotech and pharma clients.

Broad incumbents

  • Charles River Laboratories: Charles River is a large CRO offering discovery, safety assessment, and biologics services. Comparable as a partner of choice for pharma antibody programs, with the Retrogenix acquisition putting it in direct competition with Integral Molecular's specificity testing offering.
  • WuXi Biologics: WuXi Biologics is a global biologics CRO/CDMO providing antibody discovery, cell line development, and manufacturing services. Comparable as an enterprise-scale service provider for pharma antibody pipelines, with broader scope than Integral Molecular.
  • Eurofins Scientific: Eurofins is a global bioanalytical testing services group with extensive capabilities in pharmacology, ADME, and immunology. Comparable as a large-scale CRO partner for biopharma safety and specificity testing requirements.
  • GenScript ProBio: GenScript offers antibody discovery, protein production, and biologics CDMO services. Comparable in providing fee-for-service antibody discovery and protein engineering services to pharma and academic customers.
  • Crown Bioscience: Crown Bioscience is a CRO providing preclinical and translational services for oncology and immuno-oncology drug development. Comparable in offering fee-for-service research supporting therapeutic antibody development pipelines of pharmaceutical sponsors.

Emerging players

  • Alloy Therapeutics: Alloy Therapeutics operates a distributed antibody discovery platform with ATX-Gx transgenic mice, complementing Integral Molecular's chicken-based discovery. The companies are also technology partners, indicating overlap in antibody discovery infrastructure for biotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights7 records

Customer concentration

Integral Molecular social profiles

Digital presence

Integral Molecular compliance and trust

Trust signal

Compliance1 record

Integral Molecular financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Integral Molecular leadership team

Management profile

Number of profiles

Profiles11 records

Integral Molecular funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Integral Molecular M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Integral Molecular

What does Integral Molecular do?

Integral Molecular provides cell-based antibody specificity testing services using its Membrane Proteome Array (MPA) platform that screens biotherapeutics against 6,000+ human membrane proteins in unfixed cells. The company also offers therapeutic antibody discovery using the MPS platform with Lipoparticle and chicken immunization technology, high-resolution Shotgun Mutagenesis epitope mapping, Paratope-PLUS CDR-Scanning for antibody IP protection, and a portfolio of virology reagents including Reporter Virus Particles and Ready Reporter Virus kits for neutralization assays.

Is Integral Molecular a public or private company?

Integral Molecular is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Integral Molecular founded?

Integral Molecular was founded in 2001. It employs 101 to 250 people.

Where is Integral Molecular based?

Integral Molecular is headquartered in Philadelphia, United States, in the North America region.

How does Integral Molecular make money?

Four revenue lines are on record. Fee-for-Service Contract Research is the primary driver. The others are reagent and Product Sales, therapeutic Asset Licensing and success-Based Pricing.

Who are Integral Molecular's main competitors?

Direct peers on record are Retrogenix (Charles River Laboratories), AbCellera Biologics, Adimab and Antibody Solutions. Broad incumbents are Charles River Laboratories, WuXi Biologics, Eurofins Scientific, GenScript ProBio and Crown Bioscience. Alloy Therapeutics is listed as an emerging player.

Does Integral Molecular have an API?

No public API is recorded for Integral Molecular.

What industry is Integral Molecular in?

Integral Molecular's product category is Antibody Discovery and Characterization Services. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 325413 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireIntegral Molecular Launches Measles Reporter Virus Particles to Accelerate Research for TherapeuticsIntegral Molecular launched Measles Reporter Virus Particles (RVPs) to accelerate research for therapeutics. The company cites over 5,000 confirmed US measles cases this year and the loss of elimination status. RVPs enable high-throughput antibody neutralization testing without live virus.PR NewswireIntegral Molecular Celebrates 25 Years of Advancing Drug Discovery as a Cornerstone of Philadelphia's Biotech CommunityIntegral Molecular, a Philadelphia-based biotech, marks its 25th anniversary, celebrating 25 years of antibody discovery and protein engineering. The company has built a pipeline of therapeutic antibodies for cancer and other diseases, with CTIM-76, an out-licensed antibody, now in clinical testing for solid tumors. It is pursuing over 100 difficult-to-target membrane proteins.AdvfnIntegral Molecular Celebrates 25 Years of Advancing Drug Discovery as a Cornerstone of Philadelphia's Biotech CommunityIntegral Molecular, a Philadelphia-based biotech, marks its 25th anniversary, celebrating its role in advancing antibody drug discovery. The company, founded in 2001, has built tools for antibody discovery, lead optimization, and specificity testing, and its out-licensed antibody CTIM-76 is in clinical testing for solid tumors. It now pursues over 100 disease-associated membrane proteins.Third NewsIntegral Molecular Celebrates Consecutive Top Workplace Awards Recognition in Philadelphia's Biotech CommunityIntegral Molecular, a Philadelphia-based biotechnology company specializing in membrane proteins and antibody therapeutics, has been recognized as a Top Workplace by The Philadelphia Inquirer for the second consecutive year based on employee feedback surveys. Over its 25-year history, the company has contributed to the drug discovery pipelines of more than 600 biotech and pharmaceutical companies. Dr. Sharon Willis, Co-founder, stated the recognition reflects the company's commitment to scientific excellence, collaboration, and innovation.PR NewswireIntegral Molecular Earns Back-to-Back Top Workplace Honors from The Philadelphia InquirerIntegral Molecular, a Philadelphia-based biotechnology company, has been named a Top Workplace by The Philadelphia Inquirer for the second consecutive year based on confidential employee feedback. The award recognizes the company's culture of scientific excellence, collaboration, innovation, and community partnerships within Pennsylvania's life sciences ecosystem. The company stated it will continue fostering employee growth as it expands operations.MorningstarIntegral Molecular Earns Back-to-Back Top Workplace Honors from The Philadelphia InquirerIntegral Molecular was named a Top Workplace by The Philadelphia Inquirer for the second consecutive year, based on confidential employee feedback. Co-founder Sharon Willis said the award reflects the company's commitment to scientific excellence and collaboration. The company has 25 years of experience and its technologies are integrated into over 600 biotech and pharmaceutical pipelines.EIN PresswireWhat Are the Key Competitive Trends in the Research Antibodies & Reagents MarketThermo Fisher Scientific led global sales in 2024 with a 5% market share in the research antibodies and reagents market. The top 10 players accounted for 32% of total revenue, and companies are focusing on high-specificity antibody development and integration with advanced platforms.PR NewswireUSPTO Allows Antibody Genus Claims in Patent Enabled by Integral Molecular's Paratope-PLUS™ CDR-ScanningThe USPTO has allowed patent 12,545,726 B1 covering a genus of antibodies targeting the cancer antigen GPRC5D, enabled by Integral Molecular's Paratope-PLUS® CDR-Scanning technology. The patent protects a lead candidate and a family of structurally related antibodies sharing a common paratope structural feature, representing a new pathway for antibody intellectual property protection. The technology generates comprehensive experimental data by mutating each CDR residue to all 19 possible alternate amino acids, satisfying enablement and written description requirements established by the 2023 U.S. Supreme Court ruling in Amgen Inc. v. Sanofi.PR NewswireIntegral Molecular Appoints Cheryl Paes as Vice President of Commercial StrategyIntegral Molecular, a biotechnology company specializing in antibody discovery and characterization technologies, has appointed Cheryl Paes as Vice President of Commercial Strategy to lead initiatives supporting the company's commercial growth in the biotech and pharmaceutical sectors. Paes brings over 15 years of global experience in life sciences from previous roles at Meridian Life Science, Center for Breakthrough Medicines, Clarivate Analytics, and Zimmer Biomet. The appointment comes as Integral Molecular advances its Membrane Proteome Array platform toward FDA qualification and launches new services like Paratope-PLUS for antibody binding analysis.MorningstarIntegral Molecular Appoints Cheryl Paes as Vice President of Commercial StrategyIntegral Molecular, an industry leader in antibody and membrane protein discovery technologies, has appointed Cheryl Paes as Vice President of Commercial Strategy. Paes brings more than 15 years of global experience in biotechnology and life sciences, having led commercial teams at Meridian Life Science, Center for Breakthrough Medicines, Clarivate Analytics, and Zimmer Biomet. The appointment comes as the company expands its portfolio of antibody characterization technologies, including the recently launched Paratope-PLUS™ service and the Membrane Proteome Array™ platform, which is progressing toward FDA qualification.